BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
See today's BioWorld Asia
Home
» Sygnis Pulls in $24M in Rights Offering for Stroke Drug Trial
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Sygnis Pulls in $24M in Rights Offering for Stroke Drug Trial
Oct. 22, 2008
By
Cormac Sheridan
No Comments
Underlining the value of having big backers in these straitened times, Sygnis Pharma AG unveiled an €18.3 million (US$24.4 million) rights offering that already is fully backed by its two largest shareholders. (BioWorld International)
BioWorld Asia